Taipei, Taiwan

Yung-Chi Kuo

This inventor holds 1 USPTO granted patent. Top assignee: Industrial Technology Research Institute. Active years: 2021.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yung-Chi Kuo: Innovator in Galanthamine Production

Introduction

Yung-Chi Kuo is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of plant-based pharmaceuticals, particularly in the production of galanthamine, a compound with various medicinal applications.

Latest Patents

Yung-Chi Kuo holds a patent for a method of producing galanthamine by utilizing a plant. The patent, titled "Method for producing galanthamine by a plant and electrical stimulation device," outlines a process that involves performing a thermal treatment on a living plant from the Amaryllidaceae family to induce the accumulation of galanthamine. Following this, the plant is placed in a medium where electrical stimulation is applied to facilitate the release of galanthamine into the medium. This innovative approach highlights Kuo's expertise in combining botanical science with electrical technology.

Career Highlights

Kuo is affiliated with the Industrial Technology Research Institute, where he has been instrumental in advancing research in plant-based compounds. His work not only contributes to the scientific community but also has potential implications for the pharmaceutical industry.

Collaborations

Some of his notable coworkers include Wen-Yin Chen and Tsung-Lin Yang, who have collaborated with Kuo on various research projects, enhancing the scope and impact of their work.

Conclusion

Yung-Chi Kuo's innovative methods for producing galanthamine represent a significant advancement in the field of plant-based pharmaceuticals. His contributions continue to influence research and development in this important area.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…